Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why IQVIA (IQV) Stock Is Trading Up Today

2025-10-01
Shares of clinical research company IQVIA (NYSE: IQV) jumped 6.3% in the afternoon session after the company, in partnership with GSK, announced a major update to its Vaccine Track data tool for tracking adult immunization activity in the U.S. The enhancement adds local-level data for 387 metro areas and expands the dataset to a full decade of information. This update is designed to help public health organizations and providers identify immunization gaps and improve their community outreach eff

Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?

2025-10-01
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

2025-09-30
RESEARCH TRIANGLE PARK, N.C., September 30, 2025--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accomp

Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know

2025-09-30
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sel

What Makes IQVIA (IQV) an Attractive Investment?

2025-09-29
Artisan Partners, an investment management company, released its “Artisan Select Equity Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund’s Investor Class ARTNX, Advisor Class APDNX, and Institutional Class APHNX returned 6.77%, 6.76%, and 6.80%, respectively, in the second quarter, compared to a 10.94% return for the S&P […]

IQVIA Holdings Inc. stock outperforms competitors on strong trading day

2025-09-26
IQVIA Holdings Inc. stock outperforms competitors on strong trading day

IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors

2025-09-25
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors

IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors

2025-09-24
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

2025-09-19
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

What Makes IQVIA (IQV) a Good Investment?

2025-09-19
Broyhill Asset Management, an investment advisor, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Broyhill Partners appreciated 3.7% net of all fees and expenses in the second quarter, building on first-quarter gains, but falling short of the strong rally across global markets. The MSCI All Country World Index […]